TNF-Alpha Inhibition for Treatment of Alzheimer's Disease - Full Text View

Purpose

It is widely believed that inflammation contributes to the pathogenesis of AD. TNF has been implicated in both AD and neurological inflammation. Anti-TNF therapy is therefore surmised to be of potential benefit for treating AD.

Condition	Intervention	Phase
Alzheimer's Disease	Drug: etanercept given by perispinal administration	Phase I

Genetics Home Reference related topics:

Alzheimer disease

MedlinePlus related topics:

Alzheimer's Disease

Drug Information available for:

Etanercept Tumor Necrosis Factors

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study

Official Title:	Etanercept for Alzheimer's-Type Memory Loss Pilot Study

Further study details as provided by Tobinick, Edward Lewis, M.D.:

Primary Outcome Measures:

ADAS-Cog
SIB
MMSE

Secondary Outcome Measures:

Category fluency
other neuropsychological tests

Estimated Enrollment:	15
Study Start Date:	September 2004
Estimated Study Completion Date:	April 2006

Detailed Description:

Etanercept, a biologic anti-TNF fusion protein, will be administered weekly or biweekly by perispinal injection to a maximum of 15 study subjects for a period of one month, followed by a 5 month and a 6 month possible study extension, with serial testing of cognition and function monthly.

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

NINCDS-ADRDA Criteria for Alzheimer’s disease
CT or MRI consistent with AD

Exclusion Criteria:

active infection
CHF
demyelinating disease
uncontrolled diabetes mellitus
vascular dementia
clinically significant neurologic disease other than AD
Hachinski >4
history of lymphoma
TBC
wbc<2500
platelets<100,000
HCT<30
pregnancy
premenopausal, fertile not on acceptable birth control
change in neuroactive medication within 4 weeks of study initiation

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00203359

Locations


United States, California
	Edward Tobinick, MD (private medical office)
	Los Angeles, California, United States, 90095

Sponsors and Collaborators

Tobinick, Edward Lewis, M.D.

Investigators


Principal Investigator:	Edward L Tobinick, MD	unaffiliated (Assistant Clinical Professor of Medicine, David Geffen School of Medicine at UCLA)

More Information

Study ID Numbers:	10005
First Received:	September 12, 2005
Last Updated:	April 20, 2006
ClinicalTrials.gov Identifier:	NCT00203359
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Delirium, Dementia, Amnestic, Cognitive Disorders

Mental Disorders

Alzheimer Disease

Central Nervous System Diseases

TNFR-Fc fusion protein

Neurodegenerative Diseases

Brain Diseases

Dementia

Cognition Disorders

Amnesia

Delirium

Additional relevant MeSH terms:

Anti-Inflammatory Agents

Immunologic Factors

Nervous System Diseases

Physiological Effects of Drugs

Gastrointestinal Agents

Immunosuppressive Agents

Pharmacologic Actions

Analgesics, Non-Narcotic

Sensory System Agents

Therapeutic Uses

Anti-Inflammatory Agents, Non-Steroidal

Analgesics

Peripheral Nervous System Agents

Tauopathies

Antirheumatic Agents

Central Nervous System Agents

ClinicalTrials.gov processed this record on October 22, 2008

Sponsored by:	Tobinick, Edward Lewis, M.D.
Information provided by:	Tobinick, Edward Lewis, M.D.
ClinicalTrials.gov Identifier:	NCT00203359